NDRA logo

NDRA
ENDRA Life Sciences Inc

11,047
Mkt Cap
$6.09M
Volume
99,692.00
52W High
$11.96
52W Low
$2.90
PE Ratio
-0.02
NDRA Fundamentals
Price
$5.23
Prev Close
$5.90
Open
$5.77
50D MA
$5.35
Beta
1.39
Avg. Volume
699,943.30
EPS (Annual)
-$56.94
P/B
2.67
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and...
Business Wire·17d ago
News Placeholder
More News
News Placeholder
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.
Zacks·24d ago
News Placeholder
What’s Driving The Rally In NDRA Stock Today?
The company announced $4.9 million in commitments for a private placement led by institutional and cryptocurrency investors to be used to launch a digital asset treasury strategy.
Stocktwits·27d ago
News Placeholder
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Zacks·27d ago
News Placeholder
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (ENDRA or the Company), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and...
Business Wire·27d ago
News Placeholder
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), today reported financial results for the three and nine months ended September 30, 2024 and provided...
Business Wire·1y ago
News Placeholder
Study Highlighting ENDRA Life Sciences TAEUS Technology in Patients with High BMI to be Presented at AASLDs The Liver Meeting 2024
ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS), today announced the acceptance of a poster titled Noninvasive assessment of steatotic liver...
Business Wire·1y ago
News Placeholder
ENDRA Life Sciences Further Strengthens TAEUS Platform Intellectual Property with Issuance of 17th European Patent
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the 282...
Business Wire·1y ago
News Placeholder
Why ENDRA Life Sciences (NDRA) Stock Is Up 140%
ENDRA Life Sciences shares are trading higher by 147% Tuesday. The company announced the activation of a post market clinical study of the TAEUS liver system. read more...
Benzinga·1y ago
News Placeholder
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces the activation of a post market clinical study and first patient scanned with the TAEUS...
Business Wire·1y ago

Latest NDRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.